-
Response to letter ‘Lymphocyte counts and the risk of COVID-19 in people with MS’
Loonstra, F. C., van Kempen, Z. L. E., Strijbis, E. M., Killestein, J., Hoitsma, E. & Mostert, J. P., Sept 2021, In: Multiple sclerosis (Houndmills, Basingstoke, England). 27, 10, p. 1626-1627 2 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Natalizumab discontinuation in a Dutch real-world cohort
Coerver, E. M. E., Wessels, M. H. J., van Lierop, Z. Y. G., van Kempen, Z. L. E., Killestein, J. & Strijbis, E. M. M., 1 Jul 2021, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 52, p. 102974 102974.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
SARS-CoV-2 Antibodies in Adult Patients with Multiple Sclerosis in the Amsterdam MS Cohort
van Kempen, Z. L. E., Strijbis, E. M. M., Al, M. M. C. T., Steenhuis, M., Uitdehaag, B. M. J., Rispens, T. & Killestein, J., 1 Jul 2021, In: JAMA Neurology. 78, 7, p. 880-882 3 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
- All publications
